Segments (Tables)

12 Months Ended

Dec. 31, 2023


	Year ended December 31,
	2023
	North America			Europe			International Markets
	(U.S. $ in millions)
Revenues	$	8,124		$	4,837		$	1,958
Gross profit		4,421			2,726			1,050
R&D expenses		625			220			83
S&M expenses		1,005			767			420
G&A expenses		403			263			118
Other income		(8	)		(2	)		(35	)

Segment profit	$	2,396		$	1,478		$	464


	Year ended December 31,
	2022
	North America			Europe			International Markets
	(U.S. $ in millions)
Revenues	$	7,452		$	4,525		$	1,903
Gross profit		3,926			2,700			1,033
R&D expenses		532			213			72
S&M expenses		941			748			405
G&A expenses		474			246			119
Other income		(15	)		(3	)		(43	)

Segment profit	$	1,993		$	1,496		$	479


	Year ended December 31,
	2021
	North America			Europe			International Markets
	(U.S. $ in millions)
Revenues	$	7,809		$	4,886		$	2,032
Gross profit		4,226			2,823			1,118
R&D expenses		618			244			68
S&M expenses		988			846			417
G&A expenses		427			244			109
Other income		(31	)		(5	)		(5	)

Segment profit	$	2,224		$	1,494		$	529


	Year ended December 31,
	2023			2022			2021
	(U.S. $ in millions)
North America profit	$	2,396		$	1,993		$	2,224
Europe profit		1,478			1,496			1,494
International Markets profit		464			479			529

Total reportable segments profit		4,338			3,968			4,246
Profit of other activities		24			172			154

Total segments profit		4,361			4,139			4,401
Amounts not allocated to segments:
Amortization		616			732			802
Other asset impairments, restructuring and other items (1)		718			512			341
Goodwill impairment		700			2,045			—
Intangible assets impairments		350			355			424
Legal settlements and loss contingencies		1,043			2,082			717
Other unallocated amounts		502			610			402

Consolidated operating income (loss) (1)		433			(2,197	)		1,716

Financial expenses, net		1,057			966			1,058

Consolidated income (loss) before income taxes (1)	$	(624	)	$	(3,163	)	$	658

(1)	The data presented for 2022 have been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. See note 1b.

Schedule of Net Sales by Product Line

The following tables present revenues by major products and activities for each segment for the year ended December 31, 2023, 2022 and 2021:

North America segment:


	Year ended December 31,
	2023		2022		2021
	(U.S. $ in millions)
Generic products	$	3,475	$	3,549	$	3,769
AJOVY		230		218		176
AUSTEDO		1,225		963		802
BENDEKA and TREANDA		241		316		385
COPAXONE		320		387		577
Anda		1,577		1,471		1,323
Other*		1,056		549		777

Total	$	8,124	$	7,452	$	7,809

*	Other revenues were mainly comprised of a $ 500 million upfront payment received in the fourth quarter of 2023, in connection with the collaboration on Teva’s anti-TL1A asset. See note 2.

Europe segment:


	Year ended December 31,
	2023		2022		2021
	(U.S. $ in millions)
Generic products	$	3,664	$	3,466	$	3,569
AJOVY		160		124		87
COPAXONE		231		268		391
Respiratory products		265		273		356
Other*		516		393		483

Total	$	4,837	$	4,525	$	4,886

*	Other revenues in 2023 were mainly related to the sale of certain product rights.

International Markets segment:


	Year ended December 31,
	2023		2022		2021
	(U.S. $ in millions)
Generic products	$	1,594	$	1,586	$	1,649
AJOVY		44		35		50
COPAXONE		39		36		37
Other		281		246		295

Total	$	1,958	$	1,903	$	2,032

Schedule of Sales Percentage by Therapeutic Category

The following table represents the percentage of consolidated third party net sales to Teva’s major customers during the years ended December 31, 2023, 2022 and 2021.


	Percentage of Third Party Net Sales
	2023			2022			2021
McKesson Corporation		9	%		10	%		11	%
AmerisourceBergen Corporation		9	%		10	%		11	%

Schedule of Property, Plant and Equipment by Geographic Location


	December 31,
	2023		2022
	(U.S. $ in millions)
Israel	$	1,312	$	1,401
Germany		1,318		1,143
United States		596		625
Croatia		447		445
Czech republic		309		318
Hungary		279		294
Ireland		266		268
Other		1,222		1,245

Total property, plant and equipment	$	5,750	$	5,739